Treatment
Bcma Car-t clinical trials
We’re tracking 75 recruiting studies that include Bcma Car-t, each written for real people, not researchers, below.
Recruiting studies
- NCT04657861RecruitingEarly Phase 1
BCMA/TACI CAR-T for relapsed or refractory multiple myeloma
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04795882RecruitingPhase 1
Study of modular CAR T therapy for multiple myeloma
This early-phase study tests a personalized type of immune therapy called modular CAR T for people with relapsed or treatment-resistant multiple myeloma. It aims to see whether the therapy can reduce the myeloma, including in cases where standard treatments have not worked.
London, County (Optional)Ages 18 years+ - NCT06934447RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus in kids
This trial tests a new type of cell therapy, called BCMA/CD70 CAR-T, for children with lupus that hasn't improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Hangzhou, ZhejiangAges 5 years+ - NCT07715136RecruitingPhase 1
BCMA-CD19 CAR-T for Refractory Inflammatory Myopathy
This trial tests a new type of cell therapy (BCMA-CD19 cCAR-T) for people with inflammatory myopathy that hasn't improved with standard treatments. The goal is to see if this treatment can help control the disease.
Chengdu, SichuanAges 18–60 - NCT07350837RecruitingEarly Phase 1
CAR-T therapy for highly sensitized kidney transplant patients
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
Wuhan, HubeiAges 18–65 - NCT07250269RecruitingPhase 1
CAR-T therapy for AL amyloidosis
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
BeijingAges 18 years+ - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT07328581RecruitingPhase 2
CAR-T cell therapy for refractory lupus with or without kidney involvement
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
Chicago, IllinoisAges 16–70 - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT06581640RecruitingPhase 2
BCMA-targeting CAR-T cells for relapsed/refractory myeloma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Xiamen, FujianAges 18–80 - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07052565Recruiting
CAR-T cell therapy for autoimmune diseases
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
HefeiAges 18 years+ - NCT07395479RecruitingEarly Phase 1
CAR-T therapy study for advanced blood and solid cancers
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT06056102RecruitingPhase 1
CAR-T cell therapy to help highly sensitized kidney transplant patients
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
Boston, MassachusettsAges 18–65 - NCT06446128RecruitingEarly Phase 1
CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT04603872RecruitingEarly Phase 1
CAR-T plus dasatinib for hard-to-treat B-cell cancers
This early study tests a cancer-fighting treatment that uses CAR-T cells together with dasatinib for people whose B-cell cancers have come back or did not respond. It aims to improve control of the cancer in cases that are often resistant to standard treatment.
Hangzhou, ZhejiangAges 18–70 - NCT07802717RecruitingPhase 1
CAR T cell therapy for returning multiple myeloma
This trial tests a new treatment called VV169, a type of CAR T cell therapy, for people with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if it is safe and if it can help fight the cancer.
Rochester, MinnesotaAges 18 years+ - NCT07760454RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed multiple myeloma
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
Suzhou, JiangsuAges 18 years+ - NCT06515626RecruitingEarly Phase 1
Modified t cells for multiple cancers
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
Zhengzhou, HenanAges 18–75 - NCT07652138RecruitingPhase 1
RN1201 injection for newly diagnosed multiple myeloma
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
Suzhou, JiangsuAges 18–70 - NCT06783816Recruiting
New immune cell therapy for blood cancers
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Taiyuan, ShanxiAges Any age
Common questions
- Are there clinical trials studying Bcma Car-t?
- Yes. Clin2 currently lists 75 recruiting studies that include Bcma Car-t, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Bcma Car-t trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Bcma Car-t an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Bcma Car-t or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.